HLA types in patients with rheumatoid arthritis developing leucopenia after both gold and sulphasalazine treatment.
- 1 July 1989
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 48 (7) , 539-541
- https://doi.org/10.1136/ard.48.7.539
Abstract
HLA types, especially HLA-DR3, are associated with the development of toxic reactions in patients with rheumatoid arthritis after treatment with gold or D-penicillamine. In this study, after treatment with sulphasalazine, leucopenia was observed in three patients, who all had a history of leucopenia after previous gold treatment. The HLA types of these patients did not include HLA-DR3; the two patients developing mild leucopenia had HLA-DR2 and the one developing agranulocytosis had HLA-DR4.This publication has 12 references indexed in Scilit:
- GOLD-INDUCED LEUCOPENIA MAY PREDICT A SIMILAR ADVERSE REACTION TO SULPHASALAZINEThe Lancet, 1987
- HLA‐DR antigens in gold‐induced neutropeniaArthritis & Rheumatism, 1986
- Neutropenia in patients with inflammatory arthritis treated with sulphasalazine.Annals of the Rheumatic Diseases, 1986
- Sulphasalazine: a safe, effective agent for prolonged control of rheumatoid arthritis. A comparison with sodium aurothiomalate.Annals of the Rheumatic Diseases, 1985
- SulfasalazineAnnals of Internal Medicine, 1984
- Influence of previous gold toxicity on subsequent development of penicillamine toxicity.BMJ, 1982
- HLA-DR phenotype and HLA-B,DR haplotype frequencies in 704 unrelated DanesTissue Antigens, 1981
- Gold-Induced ThrombocytopeniaAnnals of Internal Medicine, 1981
- Adverse reactions to D-penicillamine after gold toxicity.BMJ, 1980
- Genetic basis of rheumatoid disease: HLA antigens, disease manifestations, and toxic reactions to drugs.BMJ, 1978